Company profile: Pionyr
1.1 - Company Overview
Company description
- Provider of immuno-oncology therapeutics that enhance antitumor immunity by targeting the tumor microenvironment. Utilizes novel target discovery and antibody generation platforms and its Myeloid Tuning approach. Programs include PY314 (TREM2) to deplete tumor-associated macrophages, PY159 (TREM1) to repolarize them to counteract immunosuppression, and PY265 (MARCO) to activate immune responses.
Products and services
- PY159: Clinical-stage program targeting TREM1 that repolarizes tumor-associated macrophages to counteract immunosuppression within the tumor microenvironment
- PY265: IND-ready program targeting MARCO to activate the immune system against the tumor microenvironment, initiating microenvironment-directed immune activation
- PY314: Clinical-stage program targeting TREM2 that depletes certain tumor-associated macrophages, enhancing anti-tumor response by modulating the tumor microenvironment
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Pionyr
Halozyme
HQ: United States
Website
- Description: Provider of extracellular matrix-targeting products and drug delivery technologies, including ENHANZE to enable subcutaneous delivery and reduce administration time vs hours-long IV infusions; HYLENEX recombinant hyaluronidase to aid dispersion and absorption of injected drugs/fluids; XYOSTED testosterone enanthate for replacement therapy; and auto-injector platforms for subcutaneous/intramuscular use, with a partner pipeline in five approved therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halozyme company profile →
Zap Surgical
HQ: United States
Website
- Description: Provider of the ZAP-X gyroscopic radiosurgery platform for treating brain tumors, lesions, and head and neck conditions, utilizing a modern linear accelerator that eliminates radioactive source replacements. Offers vault-free design to reduce infrastructure costs, dual independent gantries for >1000 non-coplanar beam angles, tungsten-shielded collimation, and SRS webinars and clinical publications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zap Surgical company profile →
Complix
HQ: Belgium
Website
- Description: Provider of Alphabody biopharmaceuticals focused on discovering and developing a novel class of therapeutics that bind with high affinity to disease targets. Offerings include Cell Penetrating Alphabodies to modulate intracellular protein interactions, a pipeline for intracellular targets in cancer, autoimmunity, and viral diseases, and anti-Covid-19 Alphabodies targeting SARS-CoV-2 fusion for prophylactic and therapeutic use.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Complix company profile →
Genocea Biosciences
HQ: United States
Website
- Description: Provider of biopharmaceutical research and development focused on novel vaccines and immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genocea Biosciences company profile →
Cernostics
HQ: United States
Website
- Description: Provider of molecular diagnostic tests for cancer, leveraging its patent-protected TissueCypher platform. TissueCypher is a laboratory-developed test that analyzes tissue from Barrett's esophagus biopsies to provide a patient's five-year risk of progression to high-grade dysplasia or esophageal adenocarcinoma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cernostics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Pionyr
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Pionyr
2.2 - Growth funds investing in similar companies to Pionyr
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Pionyr
4.2 - Public trading comparable groups for Pionyr
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →